Liraglutide investigated as add-on to insulin in autoimmune diabetes mellitus patients

Autoimmune diabetes mellitus, primarily Type 1 Diabetes (T1D), results from immune-mediated destruction of pancreatic beta-cells, leading to absolute insulin deficiency. While insulin therapy is life-sustaining, achieving optimal glycemic control and preserving residual beta-cell function remains a significant challenge, contributing to long-term complications. Glucagon-like peptide-1 (GLP-1) receptor agonists, like liraglutide, have demonstrated benefits in Type 2 Diabetes (T2D), including improved glucose homeostasis, weight loss, and potential beta-cell protective effects. This study aimed to explore if these benefits could extend to T1D patients, potentially offering an adjunctive therapy to insulin.

This retrospective chart review (NCT01299012) investigated the therapeutic effect of Liraglutide as an additional treatment to insulin in patients with newly diagnosed Type 1 Diabetes Mellitus. The study enrolled 30 patients. The intervention involved combining Liraglutide with short-term continuous subcutaneous insulin infusion (CSII), comparing this approach against CSII alone. The primary endpoints were to evaluate the impact on long-term glycemic control and β-cell function. Specific dosing, frequency, or duration of liraglutide administration were not detailed in the provided abstract.

The provided abstract and domain context describe the study's purpose and design but do not include any specific results or findings regarding the efficacy or safety of liraglutide in this patient population. Therefore, no quantitative data, p-values, or effect sizes can be reported from the available information.